Skip to content

Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis

Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00610142
Acronym
OCT-AD
Enrollment
20
Registered
2008-02-07
Start date
2007-12-31
Completion date
2009-01-31
Last updated
2014-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

atopic dermatitis, pimecrolimus, hydrocortison, Optical Coherence Tomography

Brief summary

to explore the atrophogenic potentials of hydrocortison 1% cream and pimecrolimus 1% cream on unaffected forehead skin

Interventions

twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks

DRUGhydrocortison 1% cream

twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks

Sponsors

Technische Universität Dresden
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* age 18-60 years * diagnosis of atopic dermatitis (Hanifin & Rajka Criteria) * patients with atopic dermatitis not affecting the forehead

Exclusion criteria

* pregnancy / nursing mothers * women in reproductive age without adequate contraception * severe atopic dermatitis (IGA \>= 4) * UV-Therapy in past 4 weeks * patients receiving any topical treatment on the face in past 6 month

Design outcomes

Primary

MeasureTime frame
thickness of epidermis4 weeks

Secondary

MeasureTime frame
thickness of dermis4 weeks

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026